Modality
Peptide
MOA
PLK4i
Target
KRASG12C
Pathway
Fibrosis
PAHNMOSD
Development Pipeline
Preclinical
Dec 2019
→ Dec 2030
PreclinicalCurrent
NCT06098109
1,458 pts·PAH
2019-12→2030-12·Completed
1,458 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-12-024.7y awayInterim· PAH
Trial Timeline
Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
Preclinical
Complet…
Catalysts
Interim
2030-12-02 · 4.7y away
PAH
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06098109 | Preclinical | PAH | Completed | 1458 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| BMY-4586 | Bristol-Myers Squibb | Preclinical | KRASG12C | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| AMG-4531 | Amgen | Phase 2/3 | KRASG12C | |
| AMG-2597 | Amgen | Phase 2/3 | CD38 | |
| REG-8074 | Regeneron | Phase 2/3 | KRASG12C | |
| VRT-1891 | Vertex Pharma | Phase 1 | KRASG12C | |
| Riluinavolisib | Moderna | NDA/BLA | KIF18A | |
| Pemitapinarof | BeiGene | Approved | KRASG12C | |
| ITC-6153 | Intra-Cellular | Phase 3 | KRASG12C |